330 related articles for article (PubMed ID: 25500825)
1. Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors: the referring physician's perspective.
Herrmann K; Czernin J; Wolin EM; Gupta P; Barrio M; Gutierrez A; Schiepers C; Mosessian S; Phelps ME; Allen-Auerbach MS
J Nucl Med; 2015 Jan; 56(1):70-5. PubMed ID: 25500825
[TBL] [Abstract][Full Text] [Related]
2. The Impact of 68Ga-DOTATATE PET/CT Imaging on Management of Patients with Neuroendocrine Tumors: Experience from a National Referral Center in the United Kingdom.
Skoura E; Michopoulou S; Mohmaduvesh M; Panagiotidis E; Al Harbi M; Toumpanakis C; Almukhailed O; Kayani I; Syed R; Navalkissoor S; Ell PJ; Caplin ME; Bomanji J
J Nucl Med; 2016 Jan; 57(1):34-40. PubMed ID: 26471695
[TBL] [Abstract][Full Text] [Related]
3. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
4. Impact of 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine PET/CT on managing patients with brain tumors: the referring physician's perspective.
Walter F; Cloughesy T; Walter MA; Lai A; Nghiemphu P; Wagle N; Fueger B; Satyamurthy N; Phelps ME; Czernin J
J Nucl Med; 2012 Mar; 53(3):393-8. PubMed ID: 22323780
[TBL] [Abstract][Full Text] [Related]
5. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy.
Srirajaskanthan R; Kayani I; Quigley AM; Soh J; Caplin ME; Bomanji J
J Nucl Med; 2010 Jun; 51(6):875-82. PubMed ID: 20484441
[TBL] [Abstract][Full Text] [Related]
6. Most of the Intended Management Changes After
Calais J; Czernin J; Eiber M; Fendler WP; Gartmann J; Heaney AP; Hendifar AE; Pisegna JR; Hecht JR; Wolin EM; Slavik R; Gupta P; Quon A; Schiepers C; Allen-Auerbach MS; Herrmann K
J Nucl Med; 2017 Nov; 58(11):1793-1796. PubMed ID: 28473600
[TBL] [Abstract][Full Text] [Related]
7. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors?
Has Simsek D; Kuyumcu S; Turkmen C; Sanlı Y; Aykan F; Unal S; Adalet I
J Nucl Med; 2014 Nov; 55(11):1811-7. PubMed ID: 25315243
[TBL] [Abstract][Full Text] [Related]
8. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.
Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704
[TBL] [Abstract][Full Text] [Related]
9. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial.
Etchebehere EC; de Oliveira Santos A; Gumz B; Vicente A; Hoff PG; Corradi G; Ichiki WA; de Almeida Filho JG; Cantoni S; Camargo EE; Costa FP
J Nucl Med; 2014 Oct; 55(10):1598-604. PubMed ID: 25168627
[TBL] [Abstract][Full Text] [Related]
10. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.
Sadowski SM; Neychev V; Millo C; Shih J; Nilubol N; Herscovitch P; Pacak K; Marx SJ; Kebebew E
J Clin Oncol; 2016 Feb; 34(6):588-96. PubMed ID: 26712231
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J
J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446
[TBL] [Abstract][Full Text] [Related]
12. 64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients.
Pfeifer A; Knigge U; Binderup T; Mortensen J; Oturai P; Loft A; Berthelsen AK; Langer SW; Rasmussen P; Elema D; von Benzon E; Højgaard L; Kjaer A
J Nucl Med; 2015 Jun; 56(6):847-54. PubMed ID: 25952736
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine tumor recurrence: diagnosis with 68Ga-DOTATATE PET/CT.
Haug AR; Cindea-Drimus R; Auernhammer CJ; Reincke M; Beuschlein F; Wängler B; Uebleis C; Schmidt GP; Spitzweg C; Bartenstein P; Hacker M
Radiology; 2014 Feb; 270(2):517-25. PubMed ID: 24056402
[TBL] [Abstract][Full Text] [Related]
14. The role of 68Ga-DOTATATE PET/CT in suspected neuroendocrine tumors.
Haug AR; Cindea-Drimus R; Auernhammer CJ; Reincke M; Wängler B; Uebleis C; Schmidt GP; Göke B; Bartenstein P; Hacker M
J Nucl Med; 2012 Nov; 53(11):1686-92. PubMed ID: 22984220
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors.
Deppen SA; Liu E; Blume JD; Clanton J; Shi C; Jones-Jackson LB; Lakhani V; Baum RP; Berlin J; Smith GT; Graham M; Sandler MP; Delbeke D; Walker RC
J Nucl Med; 2016 May; 57(5):708-14. PubMed ID: 26769865
[TBL] [Abstract][Full Text] [Related]
16. High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours.
Hofman MS; Kong G; Neels OC; Eu P; Hong E; Hicks RJ
J Med Imaging Radiat Oncol; 2012 Feb; 56(1):40-7. PubMed ID: 22339744
[TBL] [Abstract][Full Text] [Related]
17. A frequency and semiquantitative analysis of pathological 68Ga DOTATATE PET/CT uptake by primary site-dependent neuroendocrine tumor metastasis.
Kunikowska J; Pawlak D; Kolasa A; Mikołajczak R; Królicki L
Clin Nucl Med; 2014 Oct; 39(10):855-61. PubMed ID: 25072928
[TBL] [Abstract][Full Text] [Related]
18. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors.
Kayani I; Conry BG; Groves AM; Win T; Dickson J; Caplin M; Bomanji JB
J Nucl Med; 2009 Dec; 50(12):1927-32. PubMed ID: 19910422
[TBL] [Abstract][Full Text] [Related]
19. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
[TBL] [Abstract][Full Text] [Related]
20. Optimizing Somatostatin Receptor Imaging in Patients With Neuroendocrine Tumors: The Impact of 99mTc-HYNICTOC SPECT/SPECT/CT Versus 68Ga-DOTATATE PET/CT Upon Clinical Management.
Kunikowska J; Lewington V; Krolicki L
Clin Nucl Med; 2017 Dec; 42(12):905-911. PubMed ID: 29076910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
